Olumiant from Lilly, Incyte clears third eczema study, but who will use it?
Months ago Incyte $INCY elected to stop funding the development of Olumiant (baricitinib) — coming up with those funds became partner Eli Lilly’s problem. The JAK …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
